Company news
Kala Bio, Inc. (NASDAQ:KALA) news
Every Kala Bio, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Kala Bio and Virotek Announce Letter of Intent to Establish an Exclusive U.S. Distribution Partnership for Ophthalmology Genetic Testing ...
September 1, 2026
Kailera Therapeutics Appoints Kathleen Tregoning as Chief Corporate Affairs Officer
June 29, 2026
KALA BIO Announces Reverse Stock Split
May 7, 2026
Aterian, Inc. Announces Definitive Agreement for the Sale of its Marquee Brand Portfolio for $18 Million Subject to Adjustments
April 28, 2026
Kala Bio Celebrates Trump Executive Order as Game-Changer for Psychedelic Medicine
April 21, 2026
Kala Bio Engages Dr. Saeid Babaei as Senior Scientific Advisor to Evaluate Clinical Assets and Precision Development Opportunities
April 1, 2026
KALA BIO Delivers Industry-Leading AI Infrastructure: Bionic Intelligence Research Agent Now Live
March 30, 2026
Red Light Holland Engages Kala Bio’s Researgency.AI Platform to Support Clinical Development of Filament’s Patented PEX010 Botanical Psil...
March 18, 2026
Red Light Holland Engages Kala Bio's Researgency.ai Platform to Support Clinical Development of Filament Health's Patented PEX010 Botanic...
March 18, 2026
Kala Bio Launches a Revolution for Biotech- First AI Agent Deploying in 14 Days as $180 Billion Agentic AI Healthcare Revolution Accelerates
March 11, 2026
KALA BIO Announces Strategic Initiative to Deploy and Continue to Develop an On-Premises AI Infrastructure Platform for the Biotech Indus...
March 4, 2026
KALA BIO Settles Approximately $10.6 million of Debt
January 5, 2026
KALA BIO Announces Closing of $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
December 5, 2025
KALA BIO Announces $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
December 4, 2025
KALA BIO Enters Into $6 Million Securities Purchase Agreement with Investor David E. Lazar
December 1, 2025
KALA BIO Announces Topline Results from CHASE Phase 2b Clinical Trial Evaluating KPI-012 for the Treatment of Persistent Corneal Epitheli...
September 29, 2025
KALA BIO to Present at H.C. Wainwright 27th Annual Global Investment Conference
September 3, 2025
KALA BIO Appoints Todd Bazemore as President, Chief Executive Officer and Director
September 2, 2025
KALA BIO Reports Second Quarter 2025 Financial Results and Provides Corporate Update
August 8, 2025
KALA BIO to Present at H.C. Wainwright 5th Annual Ophthalmology Virtual Conference
August 6, 2025
KALA BIO Announces Completion of Enrollment in CHASE Clinical Trial Evaluating KPI-012 for the Treatment of Persistent Corneal Epithelial...
July 9, 2025
KALA BIO to Host Virtual Key Opinion Leader (KOL) Event to Discuss the Potential of KPI-012 for the Treatment of Persistent Corneal Epith...
July 7, 2025
KALA BIO to Present at Jefferies Global Healthcare Conference
May 29, 2025
KALA BIO Reports First Quarter 2025 Financial Results and Provides Corporate Update
May 14, 2025
KALA BIO Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
March 31, 2025
KALA BIO to Present at TD Cowen 45th Annual Health Care Conference
February 26, 2025
KALA BIO Announces Chief Executive Officer Transition
February 12, 2025
KALA BIO Announces $10,750,000 Private Placement
December 30, 2024
KALA BIO Reports Third Quarter 2024 Financial Results and Provides Corporate Update
November 12, 2024
KALA BIO Reports Second Quarter 2024 Financial Results and Provides Corporate Update
August 6, 2024
KALA BIO Announces $12,500,000 Private Placement
June 27, 2024
KALA BIO Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 14, 2024
KALA BIO Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
March 29, 2024
KALA BIO to Present at TD Cowen 44th Annual Healthcare Conference
February 26, 2024
KALA BIO to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference
February 6, 2024
KALA BIO Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 19, 2024
KALA BIO Reports Third Quarter 2023 Financial Results and Provides Corporate Update
November 13, 2023
KALA BIO to Present at H.C. Wainwright 25th Annual Global Investment Conference
September 5, 2023
KALA BIO Reports Second Quarter 2023 Financial Results and Provides Corporate Update
August 4, 2023
Kala Pharmaceuticals Announces Name Change to KALA BIO
August 2, 2023
KALA BIO to Participate in Upcoming Investor Conferences in August
August 2, 2023
Kala Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 19, 2023
Kala Pharmaceuticals to Present at the Jefferies Healthcare Conference
June 2, 2023
Kala Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
May 9, 2023
Combangio, Inc., a Wholly Owned Subsidiary of Kala Pharmaceuticals, Awarded $15 Million by California Institute for Regenerative Medicine...
April 28, 2023
Kala Pharmaceuticals Receives FDA Fast Track Designation for KPI-012, a Human MSC-S Therapy for Persistent Corneal Epithelial Defect
April 12, 2023
Kala Pharmaceuticals Appoints Dr. Francis Mah as Chief Medical Advisor
March 29, 2023
Kala Pharmaceuticals Announces Positive Safety Update from Cohort 1 of CHASE Phase 2b Clinical Trial Evaluating KPI-012 in Patients with ...
March 27, 2023
Kala Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference
March 8, 2023
Kala Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
March 3, 2023